eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | juvenile myoclonic epilepsy |
| Symptom | C0014550|myoclonic seizures |
| Sentences | 6 |
| PubMedID- 23986742 | The oral form has food and drug administration (fda) indications for adjunctive therapy in the treatment of partial onset epilepsy ages 1 month or more, myoclonic seizures associated with juvenile myoclonic epilepsy starting with the age of 12 and primary generalized tonic-clonic seizures in people 6 years and older. |
| PubMedID- 21395360 | Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizures with or without secondary generalization, and adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic (gtc) seizures associated with idiopathic generalized epilepsy. |
| PubMedID- 21936590 | Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizures with or without secondary generalization, and adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic (gtc) seizures associated with idiopathic generalized epilepsy. |
| PubMedID- 25667841 | Levetiracetam (s)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide (lev) is a second generation anticonvulsant approved by the european medicines agency (ema) and/or the u.s. food and drug administration (fda) for the following: 1) monotherapy treatment of partial seizures, with or without secondary generalization (ema); 2) adjunctive treatment of partial seizures, with or without secondary generalization (fda/ema); 3) adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy (fda/ema); and 4) adjunctive treatment of primary generalized tonic–clonic seizures associated with idiopathic generalized epilepsy (fda/ema) . |
| PubMedID- 24009559 | At present, lev is a worldwide commonly used second generation aed, approved as adjunctive and monotherapy treatment of partial-onset seizures with or without secondary generalization, and adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy (lyseng-williamson, 2011). |
| PubMedID- 24027645 | Levetiracetam is an established second-generation antiepileptic drug that is approved as a treatment of partial seizures; other indications include adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures associated with generalized epilepsy. |
Page: 1